These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 29870852)

  • 21. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
    Kovari H; Russmann S; Ledergerber B; Müller D; Rotger M; Velli P; Cavassini M; Ambrosioni J; Bregenzer A; Stöckle M; Bernasconi E; Rauch A; Speck RF;
    PLoS One; 2015; 10(7):e0133879. PubMed ID: 26218843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
    Montes ML; Nelson M; Girard PM; Sasadeusz J; Horban A; Grinsztejn B; Zakharova N; Rivero A; Durant J; Ortega-Gonzalez E; Lathouwers E; Janssen K; Ouwerkerk-Mahadevan S; Witek J; González-García J
    J Antimicrob Chemother; 2016 Jan; 71(1):244-50. PubMed ID: 26483516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.
    Piroth L; Wittkop L; Lacombe K; Rosenthal E; Gilbert C; Miailhes P; Carrieri P; Chas J; Poizot-Martin I; Gervais A; Dominguez S; Neau D; Zucman D; Billaud E; Morlat P; Aumaitre H; Lascoux-Combe C; Simon A; Bouchaud O; Teicher E; Bani-Sadr F; Alric L; Vittecoq D; Boué F; Duvivier C; Valantin MA; Esterle L; Dabis F; Sogni P; Salmon D;
    J Hepatol; 2017 Jul; 67(1):23-31. PubMed ID: 28235612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the Hepatitis C Continua of Care Between Hepatitis C Virus/HIV Coinfected and Hepatitis C Virus Mono-Infected Patients in Two Treatment Eras During 2008-2015.
    Roberson JL; Lagasca AM; Kan VL
    AIDS Res Hum Retroviruses; 2018 Feb; 34(2):148-155. PubMed ID: 28974107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.
    Monje-Agudo P; Castro-Iglesias A; Rivero-Juárez A; Martínez-Marcos F; Ortega-González E; Real LM; Pernas B; Merchante N; Cid P; Macías J; Merino MD; Rivero A; Mena A; Neukam K; Pineda JA;
    Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):1929-36. PubMed ID: 26155784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
    Rockstroh JK; Ingiliz P; Petersen J; Peck-Radosavljevic M; Welzel TM; Van der Valk M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
    Antivir Ther; 2017; 22(3):225-236. PubMed ID: 27845298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
    Townsend K; Meissner EG; Sidharthan S; Sampson M; Remaley AT; Tang L; Kohli A; Osinusi A; Masur H; Kottilil S
    AIDS Res Hum Retroviruses; 2016 May; 32(5):456-62. PubMed ID: 26559180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
    Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
    J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients.
    Labarga P; Fernandez-Montero JV; de Mendoza C; Barreiro P; Pinilla J; Soriano V
    Antivir Ther; 2015; 20(3):329-34. PubMed ID: 25372299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative impact of ribavirin monitoring and HIV coinfection on sustained virological response in patients with chronic hepatitis C.
    Piedoux S; Monnet E; Piroth L; Montange D; Royer B; Thevenot T; Kantelip JP; Di Martino V; Muret P;
    Antivir Ther; 2011; 16(8):1317-26. PubMed ID: 22155913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients.
    Hatu G; Bailly F; Pourcelot E; Pradat P; Miailhes P; Maynard M; Parant F; Chiarello P; Livrozet JM; Zoulim F; Gagnieu MC
    BMC Infect Dis; 2014 Mar; 14():150. PubMed ID: 24650094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The association of cytopenias and weight loss with hepatitis C virus virologic response in HIV/HCV-coinfected patients treated with PEG-IFN and RBV.
    Slim J; Mildvan D; Han J; Korner E
    J Int Assoc Provid AIDS Care; 2013; 12(5):354-62. PubMed ID: 23873217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients.
    De Leon LB; Tovo CV; Kliemann DA; De Mattos AA; Feltrin AA; Pacheco LS; De Almeida PR
    J Infect Dev Ctries; 2016 Aug; 10(7):762-9. PubMed ID: 27482809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.
    Sise ME; Bloom AK; Wisocky J; Lin MV; Gustafson JL; Lundquist AL; Steele D; Thiim M; Williams WW; Hashemi N; Kim AY; Thadhani R; Chung RT
    Hepatology; 2016 Feb; 63(2):408-17. PubMed ID: 26474537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
    Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
    Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
    Mira JA; Valera-Bestard B; Arizcorreta-Yarza A; González-Serrano M; Torre-Cisneros J; Santos I; Vergara S; Gutiérrez-Valencia A; Girón-González JA; Macías J; López-Cortés LF; Pineda JA
    Antivir Ther; 2007; 12(4):523-9. PubMed ID: 17668561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients.
    Bedimo R; Kang M; Tebas P; Overton ET; Hollabaugh K; McComsey G; Bhattacharya D; Evans C; Brown TT; Taiwo B
    AIDS Res Hum Retroviruses; 2016 Apr; 32(4):325-8. PubMed ID: 26499270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co-infection.
    Lodi S; Klein M; Rauch A; Epstein R; Wittkop L; Logan R; Rentsch CT; Justice AC; Touloumi G; Berenguer J; Jarrin I; Egger M; Puoti M; D'Arminio Monforte A; Gill J; Salmon Ceron D; van Sighem A; Linas B; van der Valk M; Hernán MA;
    J Int AIDS Soc; 2022 Dec; 25(12):e26048. PubMed ID: 36562643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.